TY - JOUR
T1 - Multimorbidity in Latin America and the Caribbean
T2 - A systematic review and meta-analysis
AU - Huaquiá-Diáz, Alessandra M.
AU - Chalán-Dávila, Tarick S.
AU - Carrillo-Larco, Rodrigo M.
AU - Bernabe-Ortiz, Antonio
N1 - Funding Information:
Funding RMC-L is supported by a Wellcome Trust International Training Fellowship (214185/Z/18/Z).
Publisher Copyright:
©
PY - 2021/7/23
Y1 - 2021/7/23
N2 - Objective To estimate the pooled prevalence of multimorbidity (≥2 non-communicable diseases in the same individual) among adults of the general population of Latin American and the Caribbean (LAC). Design Systematic review and meta-analysis. Data sources MEDLINE, Embase, Global Health, Scopus and LILACS up to 1 July 2020. Eligibility criteria for selecting studies The outcome was the prevalence of multimorbidity. Reports were selected whether they enrolled adult individuals (age ≥18 years) from the general population. Data extraction and synthesis Reviewers extracted relevant data and assessed risk of bias independently. A random-effects meta-analysis was conducted to report pooled prevalence estimates of multimorbidity; pooled estimates by pre-specified subgroups (eg, national studies) were also pursued. Results From 5830 results, we selected 28 reports, mostly from Brazil and 16 were based on a nationally representative sample. From the 28 selected reports, 26 were further included in the meta-analysis revealing a pooled multimorbidity prevalence of 43% (95% CI: 35% to 51%; I 2: 99.9%). When only reports with a nationally representative sample were combined, the pooled prevalence was 37% (95% CI: 27% to 47%; I 2: 99.9%). When the ascertainment of multimorbidity was based on self-reports alone, the pooled prevalence was 40% (95% CI: 31% to 48%; I 2: 99.9%); this raised to 52% (95% CI: 33% to 70%; I 2: 99.9%) for reports including self-reported and objective diagnosis. Conclusions Our results complement and advance those from global efforts by incorporating much more reports from LAC. We revealed a larger presence of multimorbidity in LAC than previously reported. PROSPERO registration number CRD42020196177.
AB - Objective To estimate the pooled prevalence of multimorbidity (≥2 non-communicable diseases in the same individual) among adults of the general population of Latin American and the Caribbean (LAC). Design Systematic review and meta-analysis. Data sources MEDLINE, Embase, Global Health, Scopus and LILACS up to 1 July 2020. Eligibility criteria for selecting studies The outcome was the prevalence of multimorbidity. Reports were selected whether they enrolled adult individuals (age ≥18 years) from the general population. Data extraction and synthesis Reviewers extracted relevant data and assessed risk of bias independently. A random-effects meta-analysis was conducted to report pooled prevalence estimates of multimorbidity; pooled estimates by pre-specified subgroups (eg, national studies) were also pursued. Results From 5830 results, we selected 28 reports, mostly from Brazil and 16 were based on a nationally representative sample. From the 28 selected reports, 26 were further included in the meta-analysis revealing a pooled multimorbidity prevalence of 43% (95% CI: 35% to 51%; I 2: 99.9%). When only reports with a nationally representative sample were combined, the pooled prevalence was 37% (95% CI: 27% to 47%; I 2: 99.9%). When the ascertainment of multimorbidity was based on self-reports alone, the pooled prevalence was 40% (95% CI: 31% to 48%; I 2: 99.9%); this raised to 52% (95% CI: 33% to 70%; I 2: 99.9%) for reports including self-reported and objective diagnosis. Conclusions Our results complement and advance those from global efforts by incorporating much more reports from LAC. We revealed a larger presence of multimorbidity in LAC than previously reported. PROSPERO registration number CRD42020196177.
KW - diabetes & endocrinology
KW - epidemiology
KW - hypertension
KW - public health
UR - http://www.scopus.com/inward/record.url?scp=85111390498&partnerID=8YFLogxK
U2 - 10.1136/bmjopen-2021-050409
DO - 10.1136/bmjopen-2021-050409
M3 - Artículo de revisión
C2 - 34301665
AN - SCOPUS:85111390498
SN - 2044-6055
VL - 11
JO - BMJ Open
JF - BMJ Open
IS - 7
M1 - e050409
ER -